Barclays PLC Spring Works Therapeutics, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 155,676 shares of SWTX stock, worth $5.54 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

155,676

Previous 155,676 -0.0%

Holding current value

$5.54 Million

Previous $4.99 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$32.04 - $42.76 $1.88 Million - $2.51 Million	58,645 Added 60.44%	155,676 $4.99 Million
Q2 2024 Aug 14, 2024	BUY	$36.06 - $47.62 $874,527 - $1.15 Million	24,252 Added 33.32%	97,031 $3.65 Million
Q1 2024 May 15, 2024	SELL	$36.5 - $52.5 $2.97 Million - $4.28 Million	-81,494 Reduced 52.82%	72,779 $3.58 Million
Q4 2023 Feb 15, 2024	BUY	$18.94 - $37.24 $1.07 Million - $2.1 Million	56,357 Added 57.56%	154,273 $5.63 Million
Q3 2023 Nov 07, 2023	SELL	$23.12 - $31.38 $551,273 - $748,224	-23,844 Reduced 19.58%	97,916 $2.27 Million
Q2 2023 Aug 03, 2023	SELL	$23.15 - $32.71 $12.4 Million - $17.5 Million	-536,105 Reduced 81.49%	121,760 $3.19 Million
Q1 2023 May 04, 2023	SELL	$24.97 - $34.05 $7.94 Million - $10.8 Million	-317,947 Reduced 32.58%	657,865 $16.9 Million
Q4 2022 Feb 13, 2023	BUY	$21.73 - $28.72 $17.9 Million - $23.6 Million	823,439 Added 540.41%	975,812 $25.4 Million
Q3 2022 Nov 03, 2022	BUY	$24.1 - $39.66 $3.36 Million - $5.53 Million	139,337 Added 1068.86%	152,373 $4.35 Million
Q2 2022 Aug 12, 2022	SELL	$18.36 - $60.07 $255,130 - $834,732	-13,896 Reduced 51.6%	13,036 $321,000
Q1 2022 May 16, 2022	BUY	$48.97 - $65.46 $1.32 Million - $1.76 Million	26,932 New	26,932 $1.52 Million

Others Institutions Holding SWTX

# of Institutions

237

Shares Held

68.9M

Call Options Held

144K

Put Options Held

257K

View Full List

About SpringWorks Therapeutics, Inc.

Ticker SWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,401,100
Market Cap $2.22B
Description
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...

More about SWTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account